SCHEMBL1397640

SCHEMBL1397640

O=C(c1cc(Cl)cc2cc[nH]c12)N(CCc1ccc(Cl)c(Cl)c1)Cc1cc2ccccc2o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.38
CHUK O15111 1/20 0.38
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 7/20 0.34
HTT P42858 2/20 0.34
TSHR P16473 2/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
C5AR1 P21730 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1397686 0.89 TP53 (0.35) IKBKBCHUKMEN1KMT2AALDH1A1
SCHEMBL1397731 0.89 TP53 (0.32) IKBKBCHUKOPRM1OPRD1MAPT
SCHEMBL1397802 0.89 MAOB (0.36) IKBKBCHUKMAPTMAOAMAOB
SCHEMBL1397655 0.89 MAPT (0.35) IKBKBCHUKMEN1KMT2AALDH1A1
SCHEMBL1397443 0.89 OPRM1 (0.31) IKBKBCHUKTSHROPRM1OPRD1
SCHEMBL1397538 0.88 THRB (0.32) IKBKBCHUKMAPTMAOB
SCHEMBL1397683 0.88 MAPT (0.33) IKBKBCHUKALDH1A1MAPTHPGD
SCHEMBL1397462 0.87 CCR2 (0.35) LMNAHPGDMAOB
SCHEMBL1397409 0.83 C5AR1 (0.38) IKBKBCHUKMEN1KMT2AFNTA
SCHEMBL1397826 0.78 C5AR1 (0.35) IKBKBCHUKMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674815-B2 Heteroaryl and benzyl amide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US claimed
EP-2007726-B1 BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS HOFFMANN LA ROCHE (CH) 2011-03-02 EP disclosed
US-7674815-B2 Heteroaryl and benzyl amide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US disclosed
EP-2007726-A2 BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-12-31 EP disclosed
WO-2007090749-A2 BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed
US-20070185113-A1 Heteroaryl and benzyl amide compounds HOFFMANN-LA ROCHE INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185113-A1 Heteroaryl and benzyl amide compounds CYP2C19, CYP2C9, CYP3A43 IKBKB 1302/4885CHUK 1212/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.